Product image of Zessly (Infliximab) supplied by GNH India

Zessly

Active Ingredient:
Infliximab
Origin:
EU

Zessly (Infliximab)

Zessly (infliximab) is a biologic medication used to reduce inflammation in conditions like rheumatoid arthritis and Crohn's disease. As an intravenous infusion, it targets specific immune pathways to help manage chronic inflammatory disorders. This biosimilar offers an alternative to reference biologics for targeted therapy.

Manufacturer / TM Owner

Sandoz Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

Indications & Clinical Uses

  • Infliximab, the active ingredient in Zessly, is prescribed to treat moderate to severe inflammatory conditions. It is commonly used for autoimmune disorders such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Zessly may also be used for Crohn's disease and ulcerative colitis when other treatments have not been effective. Patients often ask, 'What is infliximab used for?' to understand its role in managing chronic inflammation.

Side Effects

  • Zessly works by binding to TNF-alpha, a protein involved in inflammation, helping to reduce symptoms like joint pain and swelling. Many patients notice an improvement in mobility and daily functioning after starting treatment. The effects of infliximab can vary, and it may take several weeks to see noticeable changes in symptoms.

Precautions & Warnings

  • Zessly is administered by healthcare professionals in a controlled setting due to the risk of infusion reactions. Patients should inform their provider about any infections or recent vaccinations before starting treatment. Regular monitoring may be required to assess response and detect potential side effects early.

Avoid Interactions

  • Infliximab can interact with other medications that affect the immune system, such as corticosteroids or other biologics. Live vaccines should be avoided during treatment with Zessly due to the risk of infection. Patients should discuss all current medications with their healthcare provider to minimize potential interactions.

Frequently Asked Questions

Zessly is given as an intravenous infusion by a healthcare professional, typically in a clinic or hospital setting.

Common side effects may include infusion reactions, fatigue, or respiratory infections. Always consult a healthcare provider for personalized advice.

Live vaccines are generally not recommended during treatment with infliximab due to the risk of infection.

The effects of infliximab may take several weeks to become noticeable, depending on the condition being treated.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Infliximab

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT